Brief: CervoMed Inc - Phase 2B Rewind-Lb Study Underway

CervoMed

18/10/2023 12:09

Oct 18 (Reuters) - CervoMed Inc  CRVO.O :
    * CERVOMED ANNOUNCES ORAL PRESENTATION AT CTAD 2023
HIGHLIGHTING
PHASE 2B NEFLAMAPIMOD PROGRAM FOR THE TREATMENT OF PATIENTS WITH
DEMENTIA WITH LEWY BODIES
    * CERVOMED INC - PHASE 2B REWIND-LB STUDY UNDERWAY
    * CERVOMED INC - COMPLETION OF ENROLLMENT PLANNED IN 1H
2024, AND
TOPLINE PRIMARY EFFICACY RESULTS IN EXPECTED IN 2H 2024

Source text for Eikon:  ID:nPn70bX5Xa 
Further company coverage:  CRVO.O 

 ((Reuters.Briefs@thomsonreuters.com;))